Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02217735 · ClinicalTrials.gov registry record · NA
Expressive Writing for Individuals With Parkinson's Disease and Their Caregivers
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02217735 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 40 participants.
The verdict
NCT02217735, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This randomized, controlled trial (RCT) evaluates the benefits of expressive compared to neutral writing in individuals with Parkinson's Disease and their support persons. Participants will be randomly assigned to complete three, 20 minute sessions of expressive or neutral writing. Participants will complete evaluation of outcomes at baseline, immediate post, 4 month and 10 month follow ups to establish if benefits remain over time. Impact of these therapies on thinking abilities, physical health, and patient and support person ratings of thinking skills, mood and quality of life will be evaluated. Expressive writing is hypothesized to result in greater improvements and/or stability of function on neuropsychological tests of attention, working memory, learning, and memory skills compared to the neutral writing condition. Results from this study will determine whether brief writing exercises are easily used by and beneficial for individuals with Parkinson's Disease and their support persons. If positive benefit is observed, information from this study will be used to further optimize these therapies for larger trials designed to evaluate the value of the therapies for individuals with Parkinson's Disease and their support persons.
Interventions
- BEHAVIORAL Writing Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02217735
The ClinicalTrials.gov registry entry for NCT02217735 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Writing Intervention is the first listed.
NCT02217735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02217735 about?
NCT02217735 is a clinical study titled "Expressive Writing for Individuals With Parkinson's Disease and Their Caregivers". This randomized, controlled trial (RCT) evaluates the benefits of expressive compared to neutral writing in individuals with Parkinson's Disease and their support persons. Participants will be randomly assigned to complete three, 20 minute sessions of expressive or neutral writing. Participants will...
What is the current status of trial NCT02217735?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2011-08. Estimated completion is 2013-06.
What interventions are being tested in trial NCT02217735?
The interventions under investigation include: Writing Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02217735?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.